Tristan T. Timbrook

Tristan T. Timbrook, PharmD, MBA, BCPS

Academic Information

Departments Adjunct - Pharmacotherapy

Academic Office Information

tristan.timbrook@utah.edu

Board Certification

  • Board of Pharmacy Specialties (Sub: Pharmacotherapy)

Experienced antimicrobial stewardship pharmacist and outcomes researcher with a demonstrated history of working in the hospital & health care industry. Skilled in infectious diseases, molecular microbiology, outcomes modeling, and epidemiology. Research focus on comparative effectiveness and safety research, antimicrobial stewardship initiatives, big data, and understanding the relationship between microbiology diagnostics and clinical outcomes

Education History

Graduate Training University of Florida
 MSci
University of Rhode Island
 Fellow
Residency Medical University of South Carolina
 Resident
Medical University of South Carolina
 Resident
Doctoral Training Sullivan University College of Pharmacy
 PharmD
Sullivan University
 MBA
Undergraduate University of Louisville
 BA

Selected Publications

Journal Article

  1. Appaneal HJ, Luther MK, Timbrook TT, LaPlante KL, Dosa DM (2018). Facilitators and Barriers to Antibiotic Stewardship: A Qualitative Study of Pharmacists' Perspectives. Hosp Pharm, 54(4), 250-258.
  2. Timbrook TT, Burnham JP (2019). Power Calculations, Effect Sizes, and 30-Day Mortality in Enterobacteriaceae Bacteremia. JAMA Intern Med, 179(6), 849-850.
  3. Ihm C, Sutton JD, Timbrook TT, Spivak ES (2019). Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure. Open Forum Infect Dis, 6(6), ofz217.
  4. Caffrey AR, Babcock ZR, Lopes VV, Timbrook TT, LaPlante KL (2019). Heterogeneity in the treatment of bloodstream infections identified from antibiotic exposure mapping. Pharmacoepidemiol Drug Saf, 28(5), 707-715.
  5. Caffrey AR, Timbrook TT, Ali SR, Nizet V, Sakoulas G (2019). Proton-pump inhibitors do not influence clinical outcomes in patients with Staphylococcus aureus bacteremia. Therap Adv Gastroenterol, 12, 1756284819834273.
  6. Parente DM, Cunha CB, Mylonakis E, Timbrook TT (2018). Reply to Burnham, Kakol, and Vazquez-Guillamet. Clin Infect Dis, 68(7), 1251-1252.
  7. Beganovic M, Timbrook TT, Wieczorkiewicz SM (2018). Predictors of Time to Effective and Optimal Antimicrobial Therapy in Patients With Positive Blood Cultures Identified via Molecular Rapid Diagnostic Testing. Open Forum Infect Dis, 6(1), ofy350.
  8. Pawar AM, LaPlante KL, Timbrook TT, Caffrey AR (2018). Improved survival with continuation of statins in bacteremic patients. SAGE Open Med, 6, 2050312118801707.
  9. Timbrook TT, Spivak ES, Hanson KE (2018). Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship. Med Clin North Am, 102(5), 899-911.
  10. Wenzler E, Timbrook TT, Wong JR, Hurst JM, MacVane SH (2018). Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections. Am J Health Syst Pharm, 75(16), 1191-1202.
  11. Parente DM, Cunha CB, Mylonakis E, Timbrook TT (2017). The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications. Clin Infect Dis, 67(1), 1-7.
  12. Pawar AM, LaPlante KL, Timbrook TT, Caffrey AR (2018). Optimal duration for continuation of statin therapy in bacteremic patients. Ther Adv Infect Dis, 5(5), 83-90.
  13. Timbrook TT, Caffrey AR, Luther MK, Lopes V, LaPlante KL (2018). Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia. Pharmacotherapy, 38(2), 189-196.
  14. Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL (2017). Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis. Crit Care Med, 46(1), 12-20.
  15. Timbrook TT, Caffrey AR, Ovalle A, Beganovic M, Curioso W, Gaitanis M, LaPlante KL (2017). Assessments of Opportunities to Improve Antibiotic Prescribing in an Emergency Department: A Period Prevalence Survey. Infect Dis Ther, 6(4), 497-505.
  16. Parente DM, Timbrook TT, Caffrey AR, LaPlante KL (2017). Inappropriate prescribing in outpatient healthcare: an evaluation of respiratory infection visits among veterans in teaching versus non-teaching primary care clinics. Antimicrob Resist Infect Control, 6, 33.
  17. Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL (2017). Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother, 61(3).
  18. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL (2016). The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis, 64(1), 15-23.
  19. Timbrook TT, Hurst JM, Bosso JA (2016). Impact of an Antimicrobial Stewardship Program on Antimicrobial Utilization, Bacterial Susceptibilities, and Financial Expenditures at an Academic Medical Center. Hosp Pharm, 51(9), 703-711.
  20. Timbrook T, Maxam M, Bosso J (2015). Antibiotic Discontinuation Rates Associated with Positive Respiratory Viral Panel and Low Procalcitonin Results in Proven or Suspected Respiratory Infections. Infect Dis Ther, 4(3), 297-306.
  21. Timbrook T, Boger MS, Steed LL, Hurst JM (2015). Unanticipated Multiplex PCR-Based Identification of Polymicrobial Blood Culture Resulting in Earlier Isolation, Determination of Susceptibilities, and Optimization of Clinical Care. J Clin Microbiol, 53(7), 2371-3.
  22. Griffin AT, Timbrook T, Harting J, Christensen D (2013). Streptococcus anginosus group and osteomyelitis: a single centre clinical experience. Postgrad Med J, 89(1051), 262-5.